Advertisement
U.S. markets open in 5 hours 20 minutes

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.4000-0.0100 (-0.29%)
At close: 04:00PM EDT
3.3600 -0.04 (-1.18%)
After hours: 04:18PM EDT

Acasti Pharma Inc.

3009 boulevard de la Concorde East
Suite 102
Laval, QC H7E 2B5
Canada
450-687-2262
https://www.acastipharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Prashant KohliCEO & Director358.41kN/A1972
Mr. Robert J. DelAversano CPAPrincipal Financial & Accounting OfficerN/AN/A1972
Dr. R. Loch MacDonald M.D., Ph.D.Member of Scientific Advisory Board & Chief Medical OfficerN/AN/A1962
Mr. Amresh Kumar Ph.D.VP of Program ManagementN/AN/A1980
Ms. Carrie D'AndreaVP of Clinical OperationsN/AN/A1972
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Corporate Governance

Acasti Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.